Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 24084422)

1.

[Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].

Azorin JM.

Encephale. 2013 Sep;39 Suppl 2:S121-3. doi: 10.1016/S0013-7006(13)70107-6. French.

PMID:
24084422
2.

[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].

Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.

Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0. French.

PMID:
24373464
3.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
4.

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L.

BMC Psychiatry. 2013 Dec 20;13:340. doi: 10.1186/1471-244X-13-340.

5.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
6.

Long-acting injectable antipsychotics: evidence of effectiveness and use.

Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, Iyer S, Lutgens D, Banks N.

Can J Psychiatry. 2013 May;58(5 Suppl 1):5S-13S. Review.

PMID:
23945067
7.

Review of treatments that can ameliorate nonadherence in patients with schizophrenia.

Kane JM.

J Clin Psychiatry. 2006;67 Suppl 5:9-14. Review.

PMID:
16822091
8.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
9.

Long-acting injectable antipsychotics: recommendations for clinicians.

Malla A, Tibbo P, Chue P, Levy E, Manchanda R, Teehan M, Williams R, Iyer S, Roy MA.

Can J Psychiatry. 2013 May;58(5 Suppl 1):30S-5S.

PMID:
23945065
11.

Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.

Rauch AS, Fleischhacker WW.

CNS Drugs. 2013 Aug;27(8):637-52. doi: 10.1007/s40263-013-0083-9. Review.

PMID:
23780619
12.

Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.

Geerts P, Martinez G, Schreiner A.

BMC Psychiatry. 2013 Feb 17;13:58. doi: 10.1186/1471-244X-13-58.

13.

Efficacy and safety of long acting injectable atypical antipsychotics: a review.

De Berardis D, Marini S, Carano A, Lang AP, Cavuto M, Piersanti M, Fornaro M, Perna G, Valchera A, Mazza M, Iasevoli F, Martinotti G, Di Giannantonio M.

Curr Clin Pharmacol. 2013 Aug;8(3):256-64. Review.

PMID:
23343445
14.

[Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].

Schanda H, Stompe T.

Neuropsychiatr. 2010;24(1):14-26. Review. German.

PMID:
20146916
15.

Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.

Taylor M, Ng KY.

Aust N Z J Psychiatry. 2013 Jul;47(7):624-30. doi: 10.1177/0004867412470010. Epub 2012 Dec 3. Review.

PMID:
23209308
16.

[Lifelong relapse prevention with antipsychotics in schizophrenia].

Hasan A, Wobrock T.

Psychiatr Prax. 2010 Sep;37(6):268-70. doi: 10.1055/s-0030-1248517. Epub 2010 Aug 27. German. No abstract available.

PMID:
20803409
17.

Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.

Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH.

Arch Pharm Res. 2013 Jun;36(6):651-9. doi: 10.1007/s12272-013-0105-7. Epub 2013 Apr 1. Review.

PMID:
23543652
18.

Applying long-acting injectable antipsychotics in first-episode schizophrenia to achieve first remission.

Liu CC, Chiang HL, Wu SY.

CNS Drugs. 2008;22(3):257-8. No abstract available.

PMID:
18278979
19.

[Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].

Stompe T, Schanda H.

Neuropsychiatr. 2011;25(2):75-84. German.

PMID:
21672506
20.

Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.

Cañas F, Möller HJ.

Expert Opin Drug Saf. 2010 Sep;9(5):683-97. doi: 10.1517/14740338.2010.506712. Review. Erratum in: Expert Opin Drug Saf. 2010 Nov;9(6):1007.

PMID:
20690885
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk